Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21507740.2024.2326952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multimodal deep learning for predicting in-hospital mortality in heart failure patients using longitudinal chest X-rays and electronic health records.
Int J Cardiovasc Imaging
January 2025
Shanxi Cardiovascular Hospital, 18 Yifen Street, Taiyuan, 030024, Shanxi, China.
Amid an aging global population, heart failure has become a leading cause of hospitalization among older people. Its high prevalence and mortality rates underscore the importance of accurate mortality prediction for swift disease progression assessment and better patient outcomes. The evolution of artificial intelligence (AI) presents new avenues for predicting heart failure mortality.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Alzheimer's Disease International, London, United Kingdom.
Background: In 2017, all 194 Member States of the World Health Organization (WHO) unanimously adopted the Global Action Plan on the public health response to dementia 2017-2025, the primary aim being for countries to implement National Dementia Plans (NDP). However, as outlined in Alzheimer's Disease International's (ADI) recent From Plan to Impact report, WHO Member States have been far too slow to act - falling far short of the 146 countries target. In response, ADI launched the #WhatsYourPlan campaign, in collaboration with ADI Members, with the single-minded aim of galvanising governments to act on their 2017 commitment.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
McGill Centre for Studies in Aging/Translational Neuroimaging Laboratory, Montreal, QC, Canada.
Background: Dementia is a complex condition that affects individuals in various ways around the world, with a particularly high prevalence and incidence in low- to middle-income countries. However, the majority of clinical trials on immunomodulators in Alzheimer's disease have predominantly been conducted in specific geographic regions and populations. Our objective is to assess the diversity and inclusiveness of the participant samples in terminated phase 2 or 3 clinical trials for anti-amyloid therapies.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
National Institute of Neurological Disorders and Stroke, Rockville, MD, USA.
Background: Access to biospecimens is an oft cited challenge to the progress in research on neurological disorders. Access to clinical biospecimens for development of validated biomarkers and improved cellular models of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) are cited as priorities across several NIH AD/ADRD Research Implementation Milestones (https://www.nia.
View Article and Find Full Text PDFLarge multimodal models: boon or burden for low- and middle-income countries.
Int Health
January 2025
Stellenbosch University, Faculty of Medicine and Health Sciences, Francie van Zijl Drive, Parow, Cape Town 7505, South Africa.
Large multimodal models, a type of generative artificial intelligence (AI), could contribute to wider government efforts to achieve universal health coverage if ethical challenges are proactively addressed during the design and deployment of these AI technologies. The World Health Organization has published new guidance to highlight the risks and benefits of large multimodal models and recommendations to effectively govern this technology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!